{"filing":{"accession_number":"0001833141-26-000050","cik":"0001833141","ticker":"HELP","company_name":"CYBIN INC.","form":"6-K","filing_date":"2026-07-21","report_date":null,"primary_document":"cybininc-form6xk07x21x2026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833141/000183314126000050/cybininc-form6xk07x21x2026.htm"},"events":[{"id":19243,"run_id":17309,"accession_number":"0001833141-26-000050","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces completion of enrollment in the APPROACH Phase 3 pivotal study of HLP003 ahead of schedule, with topline data readout on track for Q4 2026. This is a material clinical development milestone for a clinical-stage pharmaceutical company with an FDA Breakthrough Therapy Designation candidate, representing significant progress toward potential FDA New Drug Application submission in 2028. The event is operational/strategic rather than a discrete financial event, earnings release, or executive change.","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-07-21","form":"6-K","submitted_at":null,"items":[{"id":18275,"accession_number":"0001833141-26-000050","item_number":"EX-99.1","item_title":"final2026-07x21approachenr.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of enrollment in the APPROACH Phase 3 pivotal study of HLP003 ahead of schedule, with topline data readout on track for Q4 2026. This is a material clinical development milestone for a clinical-stage pharmaceutical company with an FDA Breakthrough Therapy Designation candidate, representing significant progress toward potential FDA New Drug Application submission in 2028. The event is operational/strategic rather than a discrete financial event, earnings release, or executive change.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T21:17:37.915115+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18275,"accession_number":"0001833141-26-000050","item_number":"EX-99.1","item_title":"final2026-07x21approachenr.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of enrollment in the APPROACH Phase 3 pivotal study of HLP003 ahead of schedule, with topline data readout on track for Q4 2026. This is a material clinical development milestone for a clinical-stage pharmaceutical company with an FDA Breakthrough Therapy Designation candidate, representing significant progress toward potential FDA New Drug Application submission in 2028. The event is operational/strategic rather than a discrete financial event, earnings release, or executive change.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T21:17:37.915115+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-07-21"}]}